News Ionis to file rare disease drug after GSK declines option Firm turns down options for inotersen and IONIS-FB-LRX.
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.